Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_assertion type Assertion NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_head.
- NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_assertion description "[The anti-VEGF monoclonal antibody bevacizumab was approved in 2004 as a first-line treatment for metastatic colorectal cancer (CRC) in combination with chemotherapy and provided proof of principle for antiangiogenic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_provenance.
- NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_assertion evidence source_evidence_literature NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_provenance.
- NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_assertion SIO_000772 23579861 NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_provenance.
- NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_assertion wasDerivedFrom befree-20150227 NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_provenance.
- NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_assertion wasGeneratedBy ECO_0000203 NP772422.RAXLODC2KY8RvACElogEd1BI_PSNtstt5I5KNTrprMB88130_provenance.